CYAD Celyad SA

20.61
+0.1  (+0%)
Previous Close 20.52
Open 20.58
Price To Book 2.98
Market Cap 246191422
Shares 11,942,344
Volume 670
Short Ratio
Av. Daily Volume 4,421

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 additional data due 1H 2019.
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
Phase 1 commencement of enrollment announced November 30, 2018 with top-line data due 2H 2019.
CYAD-101 - alloSHRINK
Colorectal cancer
Phase 1 data due 2019.
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer